The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Open accessAbstract
Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are the primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after the initial treatment. In the past two decades, immunotherapy has rapidly developed, and has revolutionized the treatment of various types of cancer. Despite the fact that immunotherapy response rates among ovarian cancer patients remain modest, treatment with immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR)- and TCR-engineered T cells is rapidly developing. Therapeutic efficiency could be improved significantly if immunotherapy is included as an adjuvant therapy, in combination with chemotherapy, radiation therapy, and the use of anti-angiogenesis drugs, and poly ADP ribose polymerase inhibitors (PARPi). Newly developed technologies that identify therapeutic targets, predict treatment efficacy, rapidly screen potential immunotherapy drugs, provide neoadjuvant immunotherapy, and utilize nanomedicine technology provide new opportunities for the treatment of ovarian cancer, and have the potential to prolong patient survival. However, important issues that may hinder the efficacy of such approaches, including hyperprogressive disease (HPD), immunotherapy-resistance, and toxicity of the treatments, including neurotoxicity, must be taken into account and addressed for these therapies to be effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“The high-throughput and deep coverage of NGS techniques could help with whole exome sequencing or RNA sequencing to identify somatic mutations that may encode neoantigens (169).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Molecular analysis of the T cell repertoire (168) could digitize the immune response.”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Of Mice and Not Men: Differences between Mouse and Human Immunology
Mestas, J., & Hughes, C. C. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2731 · Cited by 3,822 · cited 1×
“have summarized the differences between mouse and human immunology in terms of both innate and adaptive immunity, including: balance of leukocyte subsets, defensins, Toll receptors, inducible NO synthase, the NK inhibitory receptor families, the B cell and T cell signaling pathway components, cytokines and cytokine re…”
BackgroundOvarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 2×
“Cancer Immunotherapy Resistance Although the overall survival rate of ovarian cancer benefits from spontaneous anti-tumor immune responses and cytotoxic T cell infiltration, the presence of clinical disease indicates that immune effector cells are insufficient to inhibit tumor growth (125, 126).”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“Currently, in order to test the clinical response to ICI therapy, there is a need to identify patients who would be expected to benefit from this immunotherapy (66, 67).”
BackgroundAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · cited 1×
“Radiation therapy-induced double-strand break DNA fragments are recognized by cyclic GMP-AMP synthase, a pattern-recognition receptor that promotes the accumulation of type I interferon (99).”
BackgroundFocan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 1×
“TAMs consist of both M1 and M2 type macrophages (25, 26).”
BackgroundMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Self-citationSotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,079
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
Cancer modeling meets human organoid technology
Tuveson, D., & Clevers, H. (2019) · Science · doi:10.1126/science.aaw6985 · Cited by 935
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835 · cited 1×
“Early preclinical trials in melanoma (185), non–small cell lung carcinoma (186), and g l iob las toma (187) have shown that neoad juvant immunotherapy was better than adjuvant immunotherapy in promoting clinical efficacy.”
Background(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Fatty acid transport protein 2 reprograms neutrophils in cancer
Veglia, F., Tyurin, V. A., Blasi, M., De Leo, A., Kossenkov, A. V., Donthireddy, L., To, T. K. J., Schug, Z., Basu, S., Wang, F., et al. (2019) · Nature · doi:10.1038/s41586-019-1118-2 · Cited by 751
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735 · cited 1×
“They found that CD14+CD16−HLA-DRhi monocytes are a strong predictor of progression-free and overall survival in response to anti–PD-1 immunotherapy (140).”
BackgroundFerrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Nanoparticle‐Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy
Chen, Q., Chen, J., Yang, Z., Xu, J., Xu, L., Liang, C., Han, X., & Liu, Z. (2019) · Advanced Materials · doi:10.1002/adma.201802228 · Cited by 661
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 596
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S.-P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 548
Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., & Di, W. (2014) · Journal of Ovarian Research · doi:10.1186/1757-2215-7-19 · Cited by 528
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis
Ladanyi, A., Mukherjee, A., Kenny, H. A., Johnson, A., Mitra, A. K., Sundaresan, S., Nieman, K. M., Pascual, G., Benitah, S. A., Montag, A., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0093-z · Cited by 517
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Mechanisms of PARP inhibitor sensitivity and resistance
D’Andrea, A. D. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.021 · Cited by 489
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
Self-citationMolecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi, J. L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B. J., Iseli, C., Dangaj, D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao5931 · Cited by 450
Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Yuen, K. C., Liu, L.-F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., Koeppen, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0860-1 · Cited by 429
Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Yin, M., Li, X., Tan, S., Zhou, H. J., Ji, W., Bellone, S., Xu, X., Zhang, H., Santin, A. D., Lou, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87252 · Cited by 417
Self-citationLo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Nowicki, T. S., Hu-Lieskovan, S., & Ribas, A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000303 · Cited by 397
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 390
Huang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Immunotherapy in ovarian cancer
Odunsi, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx444 · Cited by 384
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids
Schnalzger, T. E., de Groot, M. H., Zhang, C., Mosa, M. H., Michels, B. E., Röder, J., Darvishi, T., Wels, W. S., & Farin, H. F. (2019) · The EMBO Journal · doi:10.15252/embj.2018100928 · Cited by 354 · cited 1×
“This new preclinical model allowed testing of CAR-mediated cytotoxicity in a tissue-like environment, but further basic and clinical trials are needed to confirm these findings (162).”
BackgroundThe Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells
Miao, Y., Yang, H., Levorse, J., Yuan, S., Polak, L., Sribour, M., Singh, B., Rosenblum, M. D., & Fuchs, E. (2019) · Cell · doi:10.1016/j.cell.2019.03.025 · Cited by 299
Taki, M., Abiko, K., Baba, T., Hamanishi, J., Yamaguchi, K., Murakami, R., Yamanoi, K., Horikawa, N., Hosoe, Y., Nakamura, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03966-7 · Cited by 296
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W. J., He, Y., Liu, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0495-7 · Cited by 292
PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy
Zhang, X., Wang, C., Wang, J., Hu, Q., Langworthy, B., Ye, Y., Sun, W., Lin, J., Wang, T., Fine, J., et al. (2018) · Advanced Materials · doi:10.1002/adma.201707112 · Cited by 290
Horikawa, N., Abiko, K., Matsumura, N., Hamanishi, J., Baba, T., Yamaguchi, K., Yoshioka, Y., Koshiyama, M., & Konishi, I. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0387 · Cited by 275
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 275
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Yuan, X., Zhang, J., Li, D., Mao, Y., Mo, F., Du, W., & Ma, X. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.007 · Cited by 250
Lee, J.-M., Cimino-Mathews, A., Peer, C. J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 242
Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., & Jooss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 232
Adoptive T Cell Immunotherapy For Cancer
Perica, K., Varela, J. C., Oelke, M., & Schneck, J. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10179 · Cited by 224
Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0056 · Cited by 220
Tada, Y., Togashi, Y., Kotani, D., Kuwata, T., Sato, E., Kawazoe, A., Doi, T., Wada, H., Nishikawa, H., & Shitara, K. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0403-1 · Cited by 214
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F., & Orditura, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 211
VISTA expressed in tumour cells regulates T cell function
Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., Baba, T., Yamaguchi, K., Horikawa, N., Murakami, R., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0313-5 · Cited by 204
Chen, Y., Sun, C., Landoni, E., Metelitsa, L., Dotti, G., & Savoldo, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1811 · Cited by 204
Dai, L., Li, K., Li, M., Zhao, X., Luo, Z., Lu, L., Luo, Y., & Cai, K. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707249 · Cited by 193
Bakos, O., Lawson, C., Rouleau, S., & Tai, L.-H. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0398-7 · Cited by 192
Bollard, C. M., Tripic, T., Cruz, C. R., Dotti, G., Gottschalk, S., Torrano, V., Dakhova, O., Carrum, G., Ramos, C. A., Liu, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3179 · Cited by 181
Trial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 173
Lo, C. S., Sanii, S., Kroeger, D. R., Milne, K., Talhouk, A., Chiu, D. S., Rahimi, K., Shaw, P. A., Clarke, B. A., & Nelson, B. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1433 · Cited by 172
Single-Cell Genomics: A Stepping Stone for Future Immunology Discoveries
Giladi, A., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2017.11.011 · Cited by 168
Böhm, S., Montfort, A., Pearce, O. M. T., Topping, J. H., Chakravarty, P., Everitt, G. L. A., Clear, A. J., McDermott, J. R., Ennis, D. P., Dowe, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2657 · Cited by 168
Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors
Erez, N., Glanz, S., Raz, Y., Avivi, C., & Barshack, I. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.089 · Cited by 167
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
Gao, X., Mi, Y., Guo, N., Xu, H., Xu, L., Gou, X., & Jin, W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00774 · Cited by 167
Self-citationMi, Y., Guo, N., Luan, J., Cheng, J., Hu, Z., Jiang, P., Jin, W., & Gao, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00737 · Cited by 164
Self-citationRational combinations of immunotherapy with radiotherapy in ovarian cancer
Herrera, F. G., Irving, M. B., Kandalaft, L. E., & Coukos, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30401-2 · Cited by 162
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156
Lesterhuis, W. J., Salmons, J., Nowak, A. K., Rozali, E. N., Khong, A., Dick, I. M., Harken, J. A., Robinson, B. W. S., & Lake, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061895 · Cited by 152
Rodriguez, G. M., Galpin, K. J. C., McCloskey, C. W., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 152
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors
Fucà, G., Reppel, L., Landoni, E., Savoldo, B., & Dotti, G. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1835 · Cited by 152
Hyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 151
Mkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Abdalla, M. Y., Samara, R. N., Rotem‐Yehudar, R., Cook, L., & Khleif, S. N. (2011) · European Journal of Immunology · doi:10.1002/eji.201141639 · Cited by 149
Clinical assessment of immune-related adverse events
Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 144
Konstantinopoulos, P. A., Waggoner, S. E., Vidal, G. A., Mita, M. M., Fleming, G. F., Holloway, R. W., Le, L. V., Sachdev, J. C., Chapman‐Davis, E., Colón‐Otero, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.106 · Cited by 143
Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment
Peck, B., & Schulze, A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.007 · Cited by 143
Yang, C. Q., Xia, B.-R., Jin, W., & Lou, G. (2019) · Cancer Cell International · doi:10.1186/s12935-019-1067-8 · Cited by 138
Self-citationCai, D., Li, J., Liu, D., Hong, S., Qiao, Q., Sun, Q., Li, P., Lyu, N., Sun, T., Xie, S., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0305-2 · Cited by 136
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Adashek, J. J., Subbiah, I. M., Matos, I. G., Garralda, E., Menta, A. K., Ganeshan, D., & Subbiah, V. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.005 · Cited by 136
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 135
Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.04.555 · Cited by 131 · cited 1×
“The phase I/II basket MEDIOLA trial demonstrated that olaparib in combination with an anti–PDL1 antibody, durvalumab, for the treatment of germline BRCA 1/ 2 mutations that were platinum-sensitive resulted in relapse of ovarian cancer (116).”
BackgroundEZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Kailayangiri, S., Altvater, B., Lesch, S., Balbach, S. T., Göttlich, C., Kühnemundt, J., Mikesch, J., Schelhaas, S., Jamitzky, S., Meltzer, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.014 · Cited by 131
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Fucikova, J. P., Raková, J., Hensler, M., Kašíková, L., Belicova, L., Hladíková, K., Truxová, I., Škapa, P., Laco, J., Pecen, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4175 · Cited by 122
Development of CAR T cells designed to improve antitumor efficacy and safety
Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 117
Single-cell genomic approaches for developing the next generation of immunotherapies
Yofe, I., Dahan, R., & Amit, I. (2020) · Nature Medicine · doi:10.1038/s41591-019-0736-4 · Cited by 115
Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer
Santoiemma, P. P., Reyes, C., Wang, L.-P., McLane, M. W., Feldman, M. D., Tanyi, J. L., & Powell, D. J. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.105 · Cited by 114
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
Maintenance Treatment with Bevacizumab Prolongs Survival in anIn vivoOvarian Cancer Model
Mabuchi, S., Terai, Y., Morishige, K., Tanabe-Kimura, A., Sasaki, H., Kanemura, M., Tsunetoh, S., Tanaka, Y., Sakata, M., Burger, R. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0243 · Cited by 108
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 108
CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway
Wang, L., Zhang, F., Cui, J., Chen, L., Chen, Y., & Liu, B. (2018) · Oncology Reports · doi:10.3892/or.2018.6311 · Cited by 106
Filley, A. C., Henriquez, M. A., & Dey, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00453 · Cited by 105
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Francica, P., & Rottenberg, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0612-8 · Cited by 105
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Chen, Y., Lin, H.-W., Chien, C. L., Lai, Y.-L., Sun, W., Chen, C., & Cheng, W. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0744-4 · Cited by 103
Organoids: An intermediate modeling platform in precision oncology
Jin, M., Han, R.-R., Qiu, G., Ju, X.-C., Lou, G., & Jin, W. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.021 · Cited by 96
Self-citationArasanz, H., Zuazo, M., Bocanegra, A., Gato, M., Martínez-Aguillo, M., Morilla, I., Fernández, G., Hernández, B., López, P., Alberdi, N., et al. (2020) · Cancers · doi:10.3390/cancers12020344 · Cited by 94
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
Nersesian, S., Glazebrook, H. M., Toulany, J., Grantham, S. R., & Boudreau, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01782 · Cited by 90
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
Baert, T., Vankerckhoven, A., Riva, M., Hoylandt, A. V., Thirion, G., Gerhardt, H., Mathivet, T., Vergote, I. B., & Coosemans, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01273 · Cited by 89
Ovarian Cancer—Why Lipids Matter
Zhao, G., Cárdenas, H., & Matei, D. E. (2019) · Cancers · doi:10.3390/cancers11121870 · Cited by 89
Matuszewska, K., Santry, L. A., van Vloten, J. P., AuYeung, A. W. K., Major, P. P., Lawler, J., Wootton, S. K., Bridle, B. W., & Petrik, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0220 · Cited by 86
Gujar, S. A., Dielschneider, R. F., Clements, D. R., Helson, E., Shmulevitz, M., Marcato, P., Pan, D., Pan, L.-Z., Ahn, D., Alawadhi, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.228 · Cited by 85
Matsuda, T., Leisegang, M., Park, J.-H., Ren, L., Kato, T., Ikeda, Y., Harada, M., Kiyotani, K., Lengyel, E. R., Fleming, G. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0142 · Cited by 83
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
Xiao, Q., Nobre, A., Piñeiro, P., Berciano‐Guerrero, M., Alba, E., Cobo, M., Lauschke, V. M., & Barragán, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010286 · Cited by 83
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Papa, A., Caruso, D., Strudel, M., Tomao, F., & Tomao, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1027-1 · Cited by 80
Lau, T., Chung, T. K. H., Cheung, T., Chan, L. K., Cheung, L. W., Yim, S. F., Siu, N. S. S., Lo, K. W., Yu, M. M. Y., Kulbe, H., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4258 · Cited by 78
Nadafi, R., de Graça, C. G., Keuning, E. D., Koning, J. J., de Kivit, S., Konijn, T., Henri, S., Borst, J. G., Reijmers, R. M., van Baarsen, L. G. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.007 · Cited by 78
Immunology Driven by Large-Scale Single-Cell Sequencing
Gomes, T., Teichmann, S. A., & Talavera-López, C. N. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.09.004 · Cited by 76
Stromal Compartment as a Survival Prognostic Factor in Advanced Ovarian Carcinoma
Labiche, A., Heutte, N., Herlin, P., Chasle, J., Gauduchon, P., & Elie, N. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181bda1cb · Cited by 73
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Gogola, E., Rottenberg, S., & Jonkers, J. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050232 · Cited by 71
CAR-T cell therapy in ovarian cancer: from the bench to the bedside
Zhu, X., Cai, H., Zhao, L., Ning, L., & Lang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19929 · Cited by 69
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Lluesma, S. M., Wolfer, A., Harari, A., & Kandalaft, L. E. (2016) · Biomedicines · doi:10.3390/biomedicines4020010 · Cited by 67
Immunotherapy in ovarian cancer
Mantia-Smaldone, G. M., Corr, B. R., & Chu, C. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.20738 · Cited by 64
Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Kiyotani, K., Chan, T., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13498 · Cited by 64
Santos, J. M., Heiniö, C., Cervera-Carrascón, V., Quixabeira, D. C. A., Siurala, M., Havunen, R., Bützow, R. C., Zafar, S., de Gruijl, T. D., Lassus, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000188 · Cited by 62
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 61
Self-citationKwon, Y., Smith, B. D., Zhou, Y., Kaufman, M. D., & Godwin, A. K. (2013) · Oncogene · doi:10.1038/onc.2013.539 · Cited by 59
Boland, J. L., Zhou, Q. C., Martin, M., Callahan, M. K., Konner, J. A., O'Cearbhaill, R. E., Friedman, C. F., Tew, W. P., Makker, V., Grisham, R. N., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.11.025 · Cited by 56
Therapeutic applications of PARP inhibitors in ovarian cancer
Xie, H., Wang, W., Xia, B., Jin, W., & Lou, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110204 · Cited by 52
Self-citationBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Ojalvo, L. S., Thompson, E. D., Wang, T., Meeker, A. K., Shih, I., Fader, A. N., Cimino‐Mathews, A., & Emens, L. A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.12.010 · Cited by 47
Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes
Corradetti, B., Pisano, S., Conlan, R. S., & Mauro Ferrari, B. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254979 · Cited by 45
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 43
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms
Song, W., Das, M., & Chen, X. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.011 · Cited by 41
Hartl, C., Bertschi, A., Bou-Puerto, R., Andresen, C., Cheney, E. M., Mittendorf, E. A., Guerriero, J. L., & Goldberg, M. S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0654-5 · Cited by 40
Hinchcliff, E., Hong, D. S., Le, H., Chisholm, G. B., Iyer, R. B., Naing, A., Hwu, P., & Jazaeri, A. A. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.008 · Cited by 37
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Chrobok, M., Dahlberg, C. I. M., Sayitoğlu, E. C., Beljanski, V., Nahi, H., Gilljam, M., Stellan, B., Sütlü, T., Duru, A. D., & Alici, E. (2019) · Cancers · doi:10.3390/cancers11010069 · Cited by 29
Chae, Y. K., Oh, M. S., & Giles, F. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0354 · Cited by 28
Mlynska, A., Povilaityte, E., Zemleckaite, I., Žilionytė, K., Strioga, M. M., Kraśko, J. A., Dobrovolskienė, N., Peng, M.-W., Intaitė, B., & Pašukonienė, V. (2018) · American Journal of Reproductive Immunology · doi:10.1111/aji.12996 · Cited by 19
Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer
Nizzero, S., Shen, H., Mauro Ferrari, B., & Corradetti, B. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.008 · Cited by 17
Adaptive Resistance to Cancer Immunotherapy
McGray, A. R., & Bramson, J. L. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_14 · Cited by 15
Votanopoulos, K. I., & Skardal, A. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08351-7 · Cited by 14
Organoids: A Platform Ready for Glioblastoma Precision Medicine?
Jin, W., Jin, M., & Tu, Y. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.016 · Cited by 11
Self-citation
Metadata
- Authors
- Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-06
- Volume
- 11
- Pages
- 577869-577869
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3092122627
- Cited by
- 350
- References
- 185
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.